Democritus University of Thrace (DUTH)
Μικρολευκωματινουρία και άλλοι πρώιμοι δείκτες καρδιαγγειακής νόσου σε ασθενείς με χρόνια νεφρική ανεπάρκεια
Abstract
dc:descriptionCardiovascular disease (CVD) in chronic kidney disease (CKD) is a rising problem, which has been mainly studied in end-stage renal disease (ESRD) patients. Silent ischemic heart disease is present in 25% of these patients, while silent cardiomyopathy is the rule and congestive heart failure is present in 31% of them. Abnormal echocardiographic findings are detected in 80% of patients with significant renal dysfunction, and the major finding recorded is left ventricular hypertrophy (LVH). On the other hand, in general population ischemic heart disease is present in 5-12%, LVH in 20%, and heart failure in 5% of the population. In ESRD patients, CVD accounted for 50% of deaths during the years 2002-2004, according to the United States Renal Data System (USRDS). Furthermore, according to Levey et al. annual mortality in ESRD patients is 35 times higher than in general population (9,5% vs 0,27%), while according to Parfrey and Foley, the relative risk of death in dialysis patients is 10-100 times higher, with younger patients being in higher risk. However, increasing evidence suggest that not only significant renal dysfunction relates to increased CVD, but also patients with mild to moderate renal dysfunction are at higher risk, and they are more likely to die from CVD than reach ESRD. Considering that the prevalence of CKD stages 1-4, as recorded in the National Health and Nutrition Examination Survey in the United States, reaches 13,1% of the population, then both CKD and the accompanying CVD should be regarded as a rapidly rising major public health problem. Traditional CVD risk factors determined by the Framingham study, like hypertension, diabetes, hyperlipideamia, obesity and advanced age, are recorded more frequently in CKD patients. However, their predictive value in risk estimation is relatively low, since they can predict risk in just 50-60% of cases. The reason is that the pathogenesis of CVD in CKD is multifactorial, implicating both traditional as well as non-traditional risk factors. Therefore, in order to achieve earlier and better detection of CVD during CKD progression, the pathophysiologic mechanisms implicated should be better elucidated and understood. This will allow the determination of new biomarkers, that will reflect to the different pathogenetic mechanisms, and which could be followed in parallel to CKD progression, so that early detection of CVD or “patients at risk” would be feasible. Through this Thesis and for the first time in Greece, the prevalence of CVD in CKD stages 1-4 is recorded in a population of 221 patients from the Outpatients Clinics of three Hospitals. With the main aim being the detection and follow-up of cardiac remodelling in the course of CKD, we have revealed the presence of cardiac damage in the different CKD stages, and how biochemical and other parameters correlate to cardiac mass, between them and to CKD stages. Through these correlations, we propose pathogenetic mechanisms that are probably implicated in the pathogenesis and progression of CVD in CKD. Cardiac remodelling was detected from the very early stages of CKD, in the form of LVH, and this was mainly due to the co-morbidity in these patients, especially hypertension. As CKD progressed, the prevalence of cardiac remodelling increased and 80% of CKD 4 patients presented abnormal echocardiographic findings. The main type of cardiac remodelling progressing was concentric LVH and this was due to ageing, hypertension and cardiovascular calcifications, which led to LV diastolic dysfunction, while LV systolic function was well preserved till CKD 4. Ageing was a major aggravating factor, probably due to functional and structural changes on CV system, mainly arterial stiffening, that consequently increased systolic blood pressure (BP), LV effort and mass. Hypertension was present in 90% of patients in each CKD stage. However, as CKD progressed patients used more antihypertensives, without achieving better BP control. This was probably due to an imbalance in volume homeostasis (increase in NT-proBNP) as renal function declined, as well as due to the progressive stiffening of large arteries, caused by ageing and cardiovascular calcifications. Phosphorus, alkaline phosphatase and parathormone levels not only reflect bone disease in CKD, but they also implicate in the pathogenesis of cardiovascular calcifications, and this probably contributes to the arterial stiffening and the increase in LV effort and mass. Parathormone especially, significantly and independently correlated to LV mass, as well as indirectly through mechanisms such as vascular inflammation and endothelial dysfunction. Vascular inflammation, endothelial dysfunction and accelerated atherogenesis were three significant and related mechanisms shown to implicate in the pathogenesis of CVD in CKD. ...
Degree
thesis:*- Grantor dc:publisher
- Democritus University of Thrace (DUTH)
- Year dc:date
- 2009
Author and committee
dc:creator, dc:contributor.*- Authors dc:creator
-
- Ioannou, Kyriakos
- Ιωάννου, Κυριάκος
Subjects
dc:subject × 36- Μικρολευκωματινουρία
- Πρωτεϊνουρία
- Δείκτες καρδιαγγειακής νόσου
- Φλεγμονές
- Αθηρογένεση
- Λιπίδια
- Κυτταροκίνες
- Ενδοθηλιακή δυσλειτουργία
- Μόρια προσκόλλησης
- Νατριουρητικά πεπτίδια
- Νεφρική οστική νόσος
- Αγγειακές επασβεστώσεις
- Καρδιακή μάζα
- Υπερτροφία
- Αναδιαμόρφωση
- Χρόνια νεφρική ανεπάρκεια (ΧΝΑ)
- Microalbuminuria
- Proteinuria
- Cardiovascular risk markers
- Inflammation
- Atherogenesis
- Lipids
- Cytokines
- Endothelial dysfunction
- Adhesion molecules
- Natriuretic peptides
- Renal bone disease
- Vascular calcifications
- Cardiac mass
- Hypertrophy
- Remodelling
- Chronic renal failure (CRF)
- Ιατρική και Επιστήμες Υγείας
- Κλινική Ιατρική
- Medical and Health Sciences
- Clinical Medicine
Rights
- Language dc:language
- gre
Identifiers
dc:identifier.*- Identifier
- 10.12681/eadd/21047